At what enterprise value was DOCTOLIB acquired in 2026?

During the acquisition of DOCTOLIB by ATHOS CONSORTIUM / A.P. MOLLER HOLDING in 2026, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the TMT (Tech, Media, Telecom) industry currently tracks an average EBITDA multiple of 13.3x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DOCTOLIB when it was acquired by ATHOS CONSORTIUM / A.P. MOLLER HOLDING?

The exact EV/EBITDA multiple for DOCTOLIB is available on mynth capital. For comparison, the TMT (Tech, Media, Telecom) sector currently shows an average EBITDA multiple of 13.3x. Join our community for free to access full valuation data and industry trends.

What was the revenue of DOCTOLIB at the time of the deal?

The revenue of DOCTOLIB at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DOCTOLIB acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOCTOLIB deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.maddyness.com/2026/04/07/doctolib-depasse-les-400-millions-de-revenus-et-fait-entrer-de-nouveaux-investisseurs/

← DATABASE

Home Database TMT (Tech, Media, Telecom)DOCTOLIB

04/2026

DOCTOLIB

Acquired by

ATHOS CONSORTIUM & A.P. MOLLER HOLDING

France Software / Industry-Specific Software / Healthcare EV 3b - 100b EUR

DOCTOLIB acquired by ATHOS CONSORTIUM & A.P. MOLLER HOLDING

France Software / Industry-Specific Software / Healthcare EV 3b - 100b EUR

Context

This transaction was a significant secondary market operation, providing liquidity to early stakeholders rather than raising new capital for the company. The deal was structured to allow historical business angels and long-term employees to sell a portion of their vested shares, enabling them to realize a return on their investment and involvement since the company's inception. Concurrently, it created an entry point for a select group of new institutional investors to acquire a stake in the company without causing dilution to existing shareholders. The new investors, including Generation Investment Management, A.P. Moller Holding, and Athos KG, were specifically chosen for their deep expertise in the healthcare and technology sectors, their strong European footprint, and their alignment with the company's long-term, mission-driven strategy. This strategic diversification of the shareholder base occurred shortly after the company announced it had reached profitability, signaling a new phase of mature growth. The operation did not result in any changes to the company's governance, board composition, or strategic direction, underscoring the stability of its leadership and vision as it continues its international expansion and investment in AI technologies.

DOCTOLIB, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the TMT (Tech, Media, Telecom) sector (13.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in TMT (Tech, Media, Telecom) market trends

Target

Doctolib is a European digital health and artificial intelligence technology company headquartered in France. Founded initially as an online platform for booking medical appointments, the company has since evolved into a comprehensive provider of software-as-a-service (SaaS) solutions for the healthcare industry. Its integrated suite of tools is designed to support healthcare professionals and facilities by streamlining administrative and clinical workflows. Key offerings include practice management software, electronic patient records, secure digital communication tools, billing and claims processing, and telehealth services. The company also develops AI-powered assistants to help with tasks like clinical documentation and call management, aiming to reduce the administrative load on caregivers. Doctolib operates across several major European markets, including France, Germany, Italy, and the Netherlands, tailoring its products to comply with the specific regulatory frameworks and clinical practices of each country's healthcare system. By 2025, the company served a network of hundreds of thousands of healthcare professionals and had achieved profitability.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Other operations with DOCTOLIB

Date	Acquirer	Target	Country	Sector	Deal Context
05/2026	DOCTOLIB	MEDICUS	United Kingdom	Software	Medicus is a United Kingdom-based health technology company that has developed a next-generation clinical software platform for general practitioner (GP) surgeries operating within the National Health Service (NHS). The company distinguished itself by introducing the first new GP clinical software system to the NHS market in 25 years, challenging a long-standing duopoly of established providers. Its platform is specifically designed with and for British healthcare professionals, earning a reputation for its user-centric design, ease of use in daily operations, and close alignment with the needs of primary care teams. The software provides a comprehensive suite of functionalities, including patient scheduling, clinical documentation, care coordination, and patient follow-up. A key feature of the Medicus system is its native integration with the official NHS App, the digital portal used by millions of patients to access their health information and book appointments. This integration ensures seamless connectivity within the broader NHS digital ecosystem. In June 2025, the company's product received official validation from NHS England, formally opening the public health market for its innovative solution aimed at modernizing GP IT infrastructure and supporting a more collaborative, efficient healthcare workforce.
03/2022	BPIFRANCE / EURAZEO	DOCTOLIB	France	Software	Doctolib is a European digital health and artificial intelligence technology company headquartered in France. Founded initially as an online platform for booking medical appointments, the company has since evolved into a comprehensive provider of software-as-a-service (SaaS) solutions for the healthcare industry. Its integrated suite of tools is designed to support healthcare professionals and facilities by streamlining administrative and clinical workflows. Key offerings include practice management software, electronic patient records, secure digital communication tools, billing and claims processing, and telehealth services. The company also develops AI-powered assistants to help with tasks like clinical documentation and call management, aiming to reduce the administrative load on caregivers. Doctolib operates across several major European markets, including France, Germany, Italy, and the Netherlands, tailoring its products to comply with the specific regulatory frameworks and clinical practices of each country's healthcare system. By 2025, the company served a network of hundreds of thousands of healthcare professionals and had achieved profitability.

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOCTOLIB by ATHOS CONSORTIUM / A.P. MOLLER HOLDING are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: doctolib

Acquirer: a.p. moller holding